NCT07324473 — First Affiliated Hospital of Chongqing… cancer immunotherapy trial
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
Registry record
| Registry ID | NCT07324473 ↗ |
|---|---|
| Lead sponsor | First Affiliated Hospital of Chongqing Medical University |
| Collaborators | — |
| Phase | Phase 2 |
| Status | Not Yet Recruiting |
| Indication | Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing |
| Enrollment | 65 participants (target) |
| Start date | 2026-01-01 |
| Primary completion | 2028-01-01 (est.) |
| Last registry update | 7 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07324473), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07324473?
NCT07324473 (Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study) is registered on ClinicalTrials.gov as Phase 2, sponsored by First Affiliated Hospital of Chongqing Medical University.
Is NCT07324473 recruiting?
As of the 2026-01-07 registry update, NCT07324473 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07324473?
The lead sponsor is First Affiliated Hospital of Chongqing Medical University.
What condition does NCT07324473 study?
The registered conditions are Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing. Primary completion is listed as 2028-01-01 (estimated).
Are results available for NCT07324473?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07324473.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.